Another drug acting largely on dopamine, the VMAT2 inhibitor valbenazine, was tested in a phase IIb study in TS, but failed to meet the primary efficacy endpoint (Neurocrine Biosciences Inc., 2018). The gene discussed is SLC18A2; the disease is Timothy syndrome.